Testing effectiveness (Phase 2)Study completedNCT01203722
What this trial is testing
Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies
Who this might be right for
Hematologic Malignancies
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 87